Literature DB >> 8781877

Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study.

R C Spencer1.   

Abstract

A one-day point prevalence of infection analysis was undertaken in 1417 intensive care units (ICUs) (10,038 patients) in 17 western European countries. The prevalence of ICU-acquired infection was 20.6% (2064 patients), representing almost half the cases of infection. Pneumonia was the most commonly reported infection (46.9%), followed by infection of the lower respiratory tract (17.8%), urinary tract (17.6%), and blood (13.0%). Staphylococcus aureus was the most frequently isolated organism (30.1%), followed by Pseudomonas aeruginosa (28.7%), coagulase-negative staphylococci (19.1%), yeasts (17.1%), and enterococci (11.7%). As a group, the Enterobacteriaceae were the most commonly isolated organisms (34.4%). The study also revealed that resistance to antimicrobial agents is common among Staphylococcus aureus, Pseudomonas aeruginosa, and coagulase-negative staphylococci.

Entities:  

Mesh:

Year:  1996        PMID: 8781877     DOI: 10.1007/bf01695658

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Repeated prevalence surveys for monitoring effectiveness of hospital infection control.

Authors:  G L French; A F Cheng; S L Wong; S Donnan
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

2.  A comparison of infections in different ICUs within the same hospital.

Authors:  R B Brown; D Hosmer; H C Chen; D Teres; M Sands; S Bradley; E Opitz; D Szwedzinski; D Opalenik
Journal:  Crit Care Med       Date:  1985-06       Impact factor: 7.598

3.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

4.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

5.  The nationwide nosocomial infection rate. A new need for vital statistics.

Authors:  R W Haley; D H Culver; J W White; W M Morgan; T G Emori
Journal:  Am J Epidemiol       Date:  1985-02       Impact factor: 4.897

6.  Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia.

Authors:  S Chevret; M Hemmer; J Carlet; M Langer
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

7.  Nosocomial infections in intensive care wards: a multicenter prospective study.

Authors:  F D Daschner; P Frey; G Wolff; P C Baumann; P Suter
Journal:  Intensive Care Med       Date:  1982-01       Impact factor: 17.440

8.  Nosocomial infection among patients in different types of intensive care units at a city hospital.

Authors:  P H Chandrasekar; J A Kruse; M F Mathews
Journal:  Crit Care Med       Date:  1986-05       Impact factor: 7.598

9.  Hospital acquired infections surveillance and control in intensive care services. Results of an incidence study.

Authors:  M Costantini; P M Donisi; M G Turrin; L Diana
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  46 in total

Review 1.  Drug resistance in intensive care units.

Authors:  W C Albrich; M Angstwurm; L Bader; R Gärtner
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Frequent transmission of enterococcal strains between mechanically ventilated patients treated at an intensive care unit.

Authors:  Bodil Lund; Christina Agvald-Ohman; Anna Hultberg; Charlotta Edlund
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

5.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

Review 6.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

7.  Recognition of bacterial surface polysaccharides by lectins of the innate immune system and its contribution to defense against infection: the case of pulmonary pathogens.

Authors:  Hany Sahly; Yona Keisari; Erika Crouch; Nathan Sharon; Itzhak Ofek
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

8.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

Review 9.  Antifungal drug discovery through the study of invertebrate model hosts.

Authors:  R Pukkila-Worley; E Holson; F Wagner; E Mylonakis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Persistence of clones of coagulase-negative staphylococci among premature neonates in neonatal intensive care units: two-center study of bacterial genotyping and patient risk factors.

Authors:  C L Vermont; N G Hartwig; A Fleer; P de Man; H Verbrugh; J van den Anker; R de Groot; A van Belkum
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.